AllGenetics achieves record figures on reaching its first decade of business activity
AllGenetics & Biology SL was founded in 2011 in the business incubator of the Universidade da Coruña. Ten years later the company is well established as one of the leading genomic services providers in Europe offering tailored top-quality genomics both to public research centres and to corporate clients.
With a total number of 14 employees (50 % PhDs) AllGenetics specialises in high-throughput sequencing technologies and bioinformatic data analysis and offers genome-analysis services to a wide variety of clients, from research teams to corporations operating in different sectors such as energy production, the food industry, or crop growers.
AllGenetics' general manager Dr Joaquín Vierna highlights the company’s ability to invest over 0.1 M € in increasing production capacity in 2020 while investments in digitalisation, optimisation, R+D, and a further increase of production capacity will account for an additional 0.1 M € in late 2021 and early 2022.
The company, which is based in Oleiros (A Coruña, Spain) since January of this year, expects a sales growth of near +50 % in 2021. In the last two years, which were conditioned by the COVID-19 pandemic, the total yearly turnover reached almost 0.6 M €.
"We are very happy with our performance and strongly believe we will see AllGenetics grow over the next five years. We will most likely surpass a turnover of 1 M € shortly. We are very fortunate to have an extraordinary team of people who are totally committed to the needs of our clients. Counting on such a team of molecular biology and bioinformatics experts is what enables us to reach the highest standards of quality and this is opening doors into new markets outside the EU. When undertaking this venture ten years ago we never dreamed our company would achieve all that we have. I am especially proud of our team having created our own corporate culture and a way of interacting with one another and with our clients. This is no doubt one of our key strengths", Dr Vierna says.
Among AllGenetics' priorities for the next five years are maintaining client satisfaction levels high (> 9\10), boosting staff well-being and productivity in the workplace, and contributing to generate value locally. In terms of business strategy, AllGenetics will seek a sustainable growth path, focusing both on our traditional business areas and in developing new highly-innovative services and products in the field of genomics. A new SARS-CoV-2 variant screening service was developed by our R+D area earlier this year and a total of five additional services are currently being tested and optimised and will be launched in the third quarter of 2021.